207 related articles for article (PubMed ID: 21049059)
21. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
[TBL] [Abstract][Full Text] [Related]
23. Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
Verrest L; Wasunna M; Kokwaro G; Aman R; Musa AM; Khalil EAG; Mudawi M; Younis BM; Hailu A; Hurissa Z; Hailu W; Tesfaye S; Makonnen E; Mekonnen Y; Huitema ADR; Beijnen JH; Kshirsagar SA; Chakravarty J; Rai M; Sundar S; Alves F; Dorlo TPC
Clin Pharmacokinet; 2021 Nov; 60(11):1463-1473. PubMed ID: 34105063
[TBL] [Abstract][Full Text] [Related]
24. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
Jha TK; Olliaro P; Thakur CP; Kanyok TP; Singhania BL; Singh IJ; Singh NK; Akhoury S; Jha S
BMJ; 1998 Apr; 316(7139):1200-5. PubMed ID: 9583927
[TBL] [Abstract][Full Text] [Related]
25. A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort Study.
Abongomera C; Gatluak F; Buyze J; Ritmeijer K
PLoS One; 2016; 11(9):e0163047. PubMed ID: 27658288
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Verrest L; Roseboom IC; Wasunna M; Mbui J; Njenga S; Musa AM; Olobo J; Mohammed R; Ritmeijer K; Chu WY; Huitema ADR; Solomos A; Alves F; Dorlo TPC
J Antimicrob Chemother; 2023 Nov; 78(11):2702-2714. PubMed ID: 37726401
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.
Jamil KM; Haque R; Rahman R; Faiz MA; Bhuiyan AT; Kumar A; Hassan SM; Kelly H; Dhalaria P; Kochhar S; Desjeux P; Bhuiyan MA; Khan MM; Ghosh RS
PLoS Negl Trop Dis; 2015; 9(10):e0004118. PubMed ID: 26496648
[TBL] [Abstract][Full Text] [Related]
28. Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis.
Afzal I; Sarwar HS; Sohail MF; Varikuti S; Jahan S; Akhtar S; Yasinzai M; Satoskar AR; Shahnaz G
Nanomedicine (Lond); 2019 Feb; 14(4):387-406. PubMed ID: 30688557
[TBL] [Abstract][Full Text] [Related]
29. Interventions for Old World cutaneous leishmaniasis.
Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005067. PubMed ID: 29149474
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy for visceral leishmaniasis.
van Griensven J; Boelaert M
Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
[No Abstract] [Full Text] [Related]
31. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
Mengstie TA; Endale HT; Mulaw T; Abdella AM; Mohammed R; Malik T; Dessie G
PLoS One; 2021; 16(10):e0257229. PubMed ID: 34597312
[TBL] [Abstract][Full Text] [Related]
32. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
35. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
36. Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Edwards T; Omollo R; Khalil EA; Yifru S; Musa B; Musa A; Wasunna M; Smith PG; Royce C; Ellis S; Balasegaram M; Hailu A
Trials; 2011 Mar; 12():66. PubMed ID: 21375777
[TBL] [Abstract][Full Text] [Related]
37. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Goyal V; Burza S; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Das VNR; Bern C; Hightower A; Rijal S; Sunyoto T; Alves F; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007726. PubMed ID: 31557162
[TBL] [Abstract][Full Text] [Related]
38. Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends.
Gorski S; Collin SM; Ritmeijer K; Keus K; Gatluak F; Mueller M; Davidson RN
PLoS Negl Trop Dis; 2010 Jun; 4(6):e705. PubMed ID: 20544032
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
[TBL] [Abstract][Full Text] [Related]
40. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
